Clinical Policy: Darbepoetin Alfa (Aranesp)

Reference Number: CP.PHAR.236
Effective Date: 07.01.16
Last Review Date: 05.26
Line of Business: Commercial, HIM/ICHRA, Medicaid

Coding Implications
Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Description

Darbepoetin alfa (Aranesp®) is an erythropoiesis-stimulating agent (ESA).

FDA Approved Indication(s)

Aranesp is indicated for the treatment of:

- Anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.
- Anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.

Limitation(s) of use: Aranesp has not been shown to improve quality of life, fatigue, or patient well-being. Aranesp is not indicated for use:

- In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy.
- In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
- In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion.
- As a substitute for red blood cell transfusions in patients who require immediate correction of anemia.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Aranesp is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Anemia due to Chronic Kidney Disease (must meet all)**:**

1. Diagnosis of anemia of CKD (dialysis and non-dialysis members);
2. Prescribed by or in consultation with a hematologist or nephrologist;
3. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation ≥ 20%;
4. Pretreatment hemoglobin level < 10 g/dL;

5. Member meets both of the following (a and b):*
   **For Illinois HIM requests, the step therapy requirements below do not apply as of 1/1/2026 per IL HB 5395.*
   a. Member must use Retacrit®, unless contraindicated, clinically significant adverse effects are experienced, or Retacrit is unavailable due to shortage;
      **Prior authorization may be required for Retacrit*
   b. If member is unable to use Retacrit, member must use Epogen®, unless contraindicated or clinically significant adverse effects are experienced;
      **Prior authorization may be required for Epogen*
6. Aranesp is not prescribed concurrently with a hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor (e.g., Jesduvroq™, Vafseo®).

Approval duration:
Medicaid/HIM/ICHRA – 6 months
Commercial – 6 months or to member's renewal period, whichever is longer

B. Anemia due to Chemotherapy in Patients with Cancer (must meet all)**:**
1. Request is for use in solid or non-myeloid malignancies;
2. Member is receiving myelosuppressive chemotherapy without curative intent;
3. Prescribed by or in consultation with a hematologist or oncologist;
4. Age ≥ 18 years;
5. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation ≥ 20%;
6. Pretreatment hemoglobin < 10 g/dL;
7. Member meets one of the following (a or b):*
   **For Illinois HIM requests, the step therapy requirements below do not apply as of 1/1/2026 per IL HB 5395.*
   a. Both of the following (i and ii):
      i. Member must use Retacrit, unless contraindicated, clinically significant adverse effects are experienced, or Retacrit is unavailable due to shortage;
         **Prior authorization may be required for Retacrit*
      ii. If member is unable to use Retacrit, member must use Epogen, unless contraindicated or clinically significant adverse effects are experienced;
         **Prior authorization may be required for Epogen*
   b. Request is for treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (see *Appendix D*).

Approval duration:
Medicaid/HIM/ICHRA – 6 months or until the completion of chemotherapy course (whichever is less)
Commercial – Until the completion of chemotherapy course, 6 months, or to member's renewal date, whichever is longer

C. Anemia Associated with Myelodysplastic Syndrome (off-label) (must meet all)**:**
1. Diagnosis of anemia from myelodysplastic syndrome (MDS);
2. Prescribed by or in consultation with a hematologist or oncologist;
3. Age ≥ 18 years;
4. One of the following (a or b):
   a. Current (within the last 3 months) serum erythropoietin (EPO) ≤ 500 mU/mL;

b. Member has lower risk (IPSS low/intermediate-1) disease associated with symptomatic anemia with del(5q);

5. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation ≥ 20%;
6. Pretreatment hemoglobin < 10 g/dL;
7. Member meets one of the following (a or b):*
   **For Illinois HIM requests, the step therapy requirements below do not apply as of 1/1/2026 per IL HB 5395.*
   a. Both of the following (i and ii):
      i. Member must use Retacrit, unless contraindicated, clinically significant adverse effects are experienced, or Retacrit is unavailable due to shortage;
         **Prior authorization may be required for Retacrit*
      ii. If member is unable to use Retacrit, member must use Epogen, unless contraindicated or clinically significant adverse effects are experienced;
         **Prior authorization may be required for Epogen*
   b. Request is for treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (see *Appendix D*).

Approval duration:
Medicaid/HIM/ICHRA – 6 months
Commercial – 6 months or to member's renewal period, whichever is longer

D. Myelofibrosis-Associated Anemia (off-label) (must meet all)**:**
1. Diagnosis of anemia associated with myelofibrosis;
2. Prescribed by or in consultation with a hematologist or oncologist;
3. Age ≥ 18 years;
4. Current (within the last 3 months) serum EPO < 500 mU/mL;
5. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation ≥ 20%;
6. Pretreatment hemoglobin < 10 g/dL;
7. Member meets one of the following (a or b):*
   **For Illinois HIM requests, the step therapy requirements below do not apply as of 1/1/2026 per IL HB 5395.*
   a. Both of the following (i and ii):
      i. Member must use Retacrit, unless contraindicated, clinically significant adverse effects are experienced, or Retacrit is unavailable due to shortage;
         **Prior authorization may be required for Retacrit*
      ii. If member is unable to use Retacrit, member must use Epogen, unless contraindicated or clinically significant adverse effects are experienced;
         **Prior authorization may be required for Epogen*
   b. Request is for treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (see *Appendix D*).

Approval duration:
Medicaid/HIM/ICHRA – 6 months
Commercial – 6 months or to member's renewal period, whichever is longer

E. Other diagnoses/indications (must meet all)**:**
1. Member meets one of the following (a or b):*

**For Illinois HIM requests, the step therapy requirements below do not apply as of 1/1/2026 per IL HB 5395.*

a. Both of the following (i and ii):
   i. Member must use Retacrit, unless contraindicated, clinically significant adverse effects are experienced, or Retacrit is unavailable due to shortage;
   **Prior authorization may be required for Retacrit*
   ii. If member is unable to use Retacrit, member must use Epogen, unless contraindicated or clinically significant adverse effects are experienced;
   **Prior authorization may be required for Epogen*
b. Request is for treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (see *Appendix D*);

2. Member meets one of the following (a or b):
   a. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (i or ii):
      i. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
      ii. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
   b. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Anemia due to Chronic Kidney Disease (must meet all)**:**

1. Member meets one of the following (a or b):
   a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
   b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B);*
2. Member is responding positively to therapy;
3. Both of the following (a and b):*
   **For Illinois HIM requests, the step therapy requirements below do not apply as of 1/1/2026 per IL HB 5395.*
   a. Member must use Retacrit, unless contraindicated, clinically significant adverse effects are experienced, or Retacrit is unavailable due to shortage;
   **Prior authorization may be required for Retacrit*
   b. If member is unable to use Retacrit, member must use Epogen®, unless contraindicated or clinically significant adverse effects are experienced;
   **Prior authorization may be required for Epogen*
4. Current hemoglobin ≤ 11.5 g/dL;

5. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation ≥ 20%.
6. Aranesp is not prescribed concurrently with a hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor (e.g., Jesduvroq, Vafseo).

Approval duration:
Medicaid/HIM/ICHRA – 12 months
Commercial – 6 months or to member's renewal period, whichever is longer

B. Anemia due to Chemotherapy in Patients with Cancer (must meet all)**:**

1. Member meets one of the following (a or b):
   a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
   b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B);*
2. Member meets one of the following (a or b):*
   **For Illinois HIM requests, the step therapy requirements below do not apply as of 1/1/2026 per IL HB 5395.*
   a. Both of the following (i and ii):
      i. Member must use Retacrit, unless contraindicated, clinically significant adverse effects are experienced, or Retacrit is unavailable due to shortage;
      Prior authorization may be required for Retacrit
      ii. If member is unable to use Retacrit, member must use Epogen, unless contraindicated or clinically significant adverse effects are experienced;
      **Prior authorization may be required for Epogen*
   b. Request is for treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (see *Appendix D*);
3. Continuation of ESA therapy is concurrent with myelosuppressive chemotherapy;
4. If member has received ≥ 8 weeks of ESA therapy, member meets both of the following (a and b):
   a. Documented response to therapy as evidenced by a rise in hemoglobin levels > 1 g/dL;
   b. No RBC transfusions are required;
5. Current hemoglobin < 10 g/dL;
6. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation ≥ 20%.

Approval duration:
Medicaid/HIM/ICHRA – 6 months or until the completion of chemotherapy course (whichever is less)
Commercial – Until the completion of chemotherapy course, 6 months, or to member's renewal date, whichever is longer

C. Anemia Associated with Myelodysplastic Syndrome (off-label) (must meet all)**:**

1. Member meets one of the following (a or b):
   a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;

b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B);*

2. Member meets one of the following (a or b):*
**For Illinois HIM requests, the step therapy requirements below do not apply as of 1/1/2026 per IL HB 5395.*
   a. Both of the following (i and ii):
      i. Member must use Retacrit, unless contraindicated, clinically significant adverse effects are experienced, or Retacrit is unavailable due to shortage;
      **Prior authorization may be required for Retacrit*
      ii. If member is unable to use Retacrit, member must use Epogen, unless contraindicated or clinically significant adverse effects are experienced;
      **Prior authorization may be required for Epogen*
   b. Request is for treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (see *Appendix D*);
3. If member has received ≥ 8 weeks of ESA therapy, member meets one of the following (a or b):
   a. Documented response to therapy as evidenced by a rise in hemoglobin levels > 1.5 g/dL;
   b. Decrease of RBC transfusions requirement;
4. Current hemoglobin ≤ 12 g/dL;
5. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation ≥ 20%.

Approval duration:
Medicaid/HIM/ICHRA – 6 months
Commercial – 6 months or to member's renewal period, whichever is longer

D. Myelofibrosis-Associated Anemia (off-label) (must meet all)**:**
1. Member meets one of the following (a or b):
   a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
   b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B);*
2. Member is responding positively to therapy (examples may include, but are not limited to: for transfusion-independent members with a baseline hemoglobin < 10 g/dL, a ≥ 2 g/dL increase in hemoglobin; or for previously transfusion-dependent members, transitioning to become transfusion-independent);
3. Member meets one of the following (i or ii):*
**For Illinois HIM requests, the step therapy requirements below do not apply as of 1/1/2026 per IL HB 5395.*
   a. Both of the following (i and ii):
      i. Member must use Retacrit, unless contraindicated, clinically significant adverse effects are experienced, or Retacrit is unavailable due to shortage;
      **Prior authorization may be required for Retacrit*
      ii. If member is unable to use Retacrit, member must use Epogen, unless contraindicated or clinically significant adverse effects are experienced;
      **Prior authorization may be required for Epogen*

b. Request is for treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (see *Appendix D*);

4. Current hemoglobin ≤ 12 g/dL;
5. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation ≥ 20%.

Approval duration:
Medicaid/HIM/ICHRA – 6 months
Commercial – 6 months or to member's renewal period, whichever is longer

E. Other diagnoses/indications (must meet all)**:**

1. Member meets one of the following (a or b):*
   **For Illinois HIM requests, the step therapy requirements below do not apply as of 1/1/2026 per IL HB 5395.*
   a. Both of the following (i and ii):
      i. Member must use Retacrit, unless contraindicated, clinically significant adverse effects are experienced, or Retacrit is unavailable due to shortage;
      **Prior authorization may be required for Retacrit*
      ii. If member is unable to use Retacrit, member must use Epogen, unless contraindicated or clinically significant adverse effects are experienced;
      **Prior authorization may be required for Epogen*
   b. Request is for treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (see *Appendix D*);
2. Member meets one of the following (a or b):
   a. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (i or ii):
      i. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
      ii. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
   b. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

CKD: chronic kidney disease
EPO: erythropoietin
ESA: erythropoiesis-stimulating agent
FDA: Food and Drug Administration
IPSS: International Prognostic Scoring System
MDS: myelodysplastic syndrome

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Retacrit (epoetin alfa-epbx), Epogen (epoetin alfa)	Anemia due to CKD Initial dose: 50 to 100 Units/kg 3 times weekly (adults) IV or SC and 50 Units/kg 3 times weekly (pediatric patients ages 1 month or older) IV or SC. Individualize maintenance dose. IV route recommended for patients on hemodialysis Anemia due to chemotherapy 40,000 Units SC weekly or 150 Units/kg SC 3 times weekly (adults); 600 Units/kg IV weekly (pediatric patients 5 to 18 years) until completion of a chemotherapy course Anemia associated with MDS† 40,000 to 60,000 Units SC 1-2 times weekly Anemia associated with myelofibrosis† In a clinical trial, patients initially received erythropoietin 10,000 units SC 3 days per week. Erythropoietin was increased to 20,000 units 3 days per week if a response was not obtained after 2 months and erythropoietin was discontinued in patients who did not experience a response at 3 months.	Varies depending on indication, frequency of administration, and individual response

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.
†Off-label indication

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): uncontrolled hypertension, pure red cell aplasia that begins after treatment with Aranesp or other erythropoietin protein drugs, serious allergic reactions
- Boxed warning(s): ESAs increase the risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access and tumor progression or recurrence

Appendix D: States with Regulations against Redirections in Cancer

State	Step Therapy Prohibited?	Notes
FL	Yes	For stage 4 metastatic cancer and associated conditions.
GA	Yes	For stage 4 metastatic cancer. Redirection does not refer to review of medical necessity or clinical appropriateness.
IA	Yes	For standard of care stage 4 cancer drug use, supported by peer-reviewed, evidence-based literature, and approved by FDA.
IN	Yes	For advanced, metastatic cancer and associated conditions
LA	Yes≠	For stage 4 advanced, metastatic cancer or associated conditions. ≠Exception if clinically equivalent therapy, contains identical active ingredient(s), and proven to have same efficacy.
MS	Yes	For advanced metastatic cancer and associated conditions
NV	Yes	Stage 3 and stage 4 cancer patients for a prescription drug to treat the cancer or any symptom thereof of the covered person
OH	Yes	For stage 4 metastatic cancer and associated conditions
OK	Yes	For advanced metastatic cancer and associated conditions
PA	Yes	For stage 4 advanced, metastatic cancer
TN	Yes^	For cancer and associated conditions ^Exception if step therapy is for AB-rated generic equivalent, interchangeable biological product, or biosimilar product to the equivalent brand drug
TX	Yes	For stage 4 advanced, metastatic cancer and associated conditions

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Anemia due to CKD	CKD on dialysis: starting dose 0.45 mcg/kg IV or SC weekly, or 0.75 mcg/kg IV or SC every 2 weeks. IV recommended for patients on hemodialysis CKD not on dialysis: starting dose 0.45 mcg/kg IV or SC at 4 week intervals Pediatric patients with CKD: starting dose 0.45 mcg/kg IV or SC weekly; patients with CKD not on dialysis may also be initiated at 0.75 mcg/kg every 2 weeks	Varies depending on indication and frequency of administration.

Indication	Dosing Regimen	Maximum Dose
Anemia due to chemotherapy in patients with cancer	Starting dose: 2.25 mcg/kg SC weekly, or 500 mcg SC every 3 weeks until completion of a chemotherapy course	
Anemia associated with MDS†	150-300 mcg SC every other week	500 mcg every other week

†*Off-label NCCN recommended use*

VI. Product Availability

- Single-dose vials for injection: 25 mcg, 40 mcg, 60 mcg, 100 mcg, 200 mcg
- Single dose prefilled syringes for injection: 10 mcg/0.4 mL, 25 mcg/0.42 mL, 40 mcg/0.4 mL, 60 mcg/0.3 mL, 100 mcg/0.5 mL, 150 mcg/0.3 mL, 200 mcg/0.4 mL, 300 mcg/0.6 mL, and 500 mcg/1 mL

VII. References

1. Aranesp Prescribing Information. Thousand Oaks, CA: Amgen Inc.; December 2024. Available at http://www.aranesp.com/. Accessed January 12, 2026.
2. Bohlius J, Bohlke K, Castelli R, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update: Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents. 2019 May 20; J Clin Oncol 37:1336-1351. Available at: https://ascopubs.org/doi/pdf/10.1200/JCO.18.02142. Accessed February 25, 2025.
3. Darbepoetin alfa. In: National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at www.nccn.org. Accessed February 18, 2026.
4. Myelodysplastic Syndromes (Version 3.2026). In: National Comprehensive Cancer Network Guidelines. Available at https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. Accessed February 18, 2026.
5. Myeloproliferative Neoplasms (Version 1.2026). In National Comprehensive Cancer Network Guidelines. Available at https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf. Accessed February 18, 2026.
6. Hematopoietic Growth Factors (Version 3.2026). In National Comprehensive Cancer Network Guidelines. Available at https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf. Accessed February 18, 2026.
7. Clinical Pharmacology [database online]. Philadelphia, PA: Elsevier. Updated periodically. Available at: https://www.clinicalkey.com/pharmacology/. Accessed February 18, 2026.
8. Micromedex® Healthcare Series [Internet database]. Ann Arbor, Michigan: Merative™. Updated periodically. Accessed February 18, 2026.
9. Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Official Journal of the International Society of Nephrology – Kidney International Supplements August 2012. 2(4): 279-335.
10. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO 2026 clinical practice guideline for the management of anemia in chronic kidney disease (CKD). Kidney Int. 2026 Jan;109(1S):S1-S99. doi: 10.1016/j.kint.2025.06.006.

Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J0881	Injection, darbepoetin alfa, 1 mcg (non-ESRD use)
J0882	Injection, darbepoetin alfa, 1 mcg (for ESRD on dialysis)

Reviews, Revisions, and Approvals	Date	P&T Approval Date
2Q 2022 annual review: for CKD removed redirection bypass for stage IV or metastatic cancer as it is not applicable for this indication; references reviewed and updated.	04.27.22	05.22
Template changes applied to other diagnoses/indications and continued therapy section.	10.07.22	
2Q 2023 annual review: per NCCN for MDS continuation of therapy modified treatment response assessment to occur after at least 8 weeks of therapy (previously this was 12 weeks); per NCCN Compendium for MDS added approval pathway for lower risk (IPSS low/intermediate-1) disease associated with symptomatic anemia with del(5q); references reviewed and updated.	02.01.23	05.23
Updated Appendix E to include Oklahoma.	06.07.23	
2Q 2024 annual review: for anemia associated with myelofibrosis, added requirement that pretreatment hemoglobin < 10 g/dL for initial requests and current hemoglobin ≤ 12 g/dL for continuation requests; for anemia due to CKD, added requirement for continuation requests that current hemoglobin ≤ 12 g/dL; references reviewed and updated.	01.09.24	05.24
Updated Appendix E to include Mississippi.	06.05.24	
2Q 2025 annual review: extended continuation of therapy approval duration from 6 to 12 months for Medicaid/HIM for anemia due to CKD; removed 300 mg vial from product availability per updated prescribing information; references reviewed and updated. Per March SDC, for all indications, revised Retacrit and Epogen redirection language from "failure of" to "member must use" and revised criteria from "member meets one of the following" to "member must meet both of the following", clarified members must use Epogen if member is unable to use Retacrit. Added step therapy bypass for IL HIM per IL HB 5395.	03.11.25	05.25
2Q 2026 annual review: for continuation of therapy request for anemia associated with CKD, modified current hemoglobin requirement from ≤ 12 g/dL to ≤ 11.5 g/dL; for anemia associated with CKD, added requirement that requested product is not prescribed concurrently with	04.23.26	05.26

Reviews, Revisions, and Approvals	Date	P&T Approval Date
a hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor; references reviewed and updated. For Appendix D, added state IN. Added ICHRA line of business.		
Updated Appendix D with revised language for Tennessee.	06.24.26	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. "Health Plan" means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.